PYRROLOPYRIMIDINE AND PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP

[PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against C RF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disea...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	DE BRUYN, MARCEL F. L, YAMAGUCHI, MIKAKO, BONGARTZ, JEAN-PIERRE A. M, HENDRICKX, ROBERT J. M, OKUBO, TAKETOSHI, LUYCKX, MARCEL G. M, NAKAZATO, ATSURO, NOZAWA, DAI, TAMITA, TOMOKO, VAN DEN KEYBUS, FRANS M. A, VAN ROOSBROECK, YVES E. M, KENNIS, LUDO E. J
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAININGELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN,SULFUR, SELENIUM OR TELLURIUM CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	[PROBLEM TO BE SOLVED] An object of the present invention is to provide an antagonist against C RF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. [SOLUTION] A pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cycl ic amino group represented by the following formula [I]: (see formula I) has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.